• LAST PRICE
    4.0600
  • TODAY'S CHANGE (%)
    Trending Down-0.0400 (-0.9756%)
  • Bid / Lots
    4.0000/ 2
  • Ask / Lots
    4.3900/ 1
  • Open / Previous Close
    3.9500 / 4.1000
  • Day Range
    Low 3.8832
    High 4.4582
  • 52 Week Range
    Low 2.7000
    High 6.4738
  • Volume
    10,300
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Wednesday's close: 4.1
TimeVolumeLBPH
09:32 ET5724
11:05 ET6004.1
11:07 ET21964.1
11:21 ET1004.34
11:30 ET10134.31
11:32 ET6004.35
11:34 ET11924.3401
12:12 ET3004.31
12:19 ET3234.29
12:30 ET1234.06
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesLBPH
Longboard Pharmaceuticals Inc
70.6M
-1.7x
---
United StatesGALT
Galectin Therapeutics Inc
70.7M
-1.9x
---
United StatesPVCT
Provectus Biopharmaceuticals Inc
71.3M
-13.4x
---
United StatesXFOR
X4 Pharmaceuticals Inc
71.3M
-0.4x
---
United StatesDBTX
Decibel Therapeutics Inc
71.4M
-1.2x
---
United StatesGMTX
Gemini Therapeutics Inc
71.5M
-1.6x
---
As of 2022-12-08

Company Information

Longboard Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing medicines for neurological diseases. Its pipelines includes LP352, LP143 and LP659. LP352 is an oral, centrally acting, 5-hydroxytryptamine 2c receptor subtype (5-HT2c) superagonist for the treatment of developmental and epileptic encephalopathies (DEEs), including Dravet syndrome and Lennox-Gastaut syndrome, among others. LP143 is a centrally acting, full cannabinoid type 2 receptor (CB2) agonist in investigational new drug application (IND)-enabling studies for neurodegenerative diseases associated with neuroinflammation caused by microglial activation, including amyotrophic lateral sclerosis (ALS). LP659 is a centrally acting, sphingosine-1-phosphate (S1P) receptor subtypes 1 and 5 (S1P1,5) modulator in IND-enabling studies for central nervous system (CNS) neuroinflammatory diseases.

Contact Information

Headquarters
4275 Executive Square, Suite 950LA JOLLA, CA, United States 92037
Phone
619-592-9775
Fax
302-636-5454

Executives

Independent Chairman of the Board
Paul Sekhri
President, Chief Executive Officer, Director
Kevin Lind
Chief Financial Officer
Brandi Roberts
Chief Medical Officer
Randall Kaye
Director
Vincent Aurentz

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$70.6M
Revenue (TTM)
$0.00
Shares Outstanding
17.2M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
---
EPS
$-2.42
Book Value
$6.05
P/E Ratio
-1.7x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.